<DOC>
	<DOC>NCT00046943</DOC>
	<brief_summary>RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. PURPOSE: Phase III trial to determine the effectiveness of atrasentan in treating patients who have prostate cancer that has not responded to hormone therapy.</brief_summary>
	<brief_title>Atrasentan in Treating Patients With Prostate Cancer</brief_title>
	<detailed_description>OBJECTIVES: - Determine the safety of atrasentan in patients with hormone-refractory prostate cancer. - Determine the pharmacokinetics of this drug in these patients. OUTLINE: This is an open-label, multicenter study. Patients receive oral atrasentan once daily for 3 years in the absence of disease progression or unacceptable toxicity. Patients are followed at 1 month and then every 3 months for 2 years. PROJECTED ACCRUAL: Approximately 1,400 patients will be accrued for this study.</detailed_description>
	<mesh_term>Prostatic Neoplasms</mesh_term>
	<mesh_term>Atrasentan</mesh_term>
	<criteria>DISEASE CHARACTERISTICS: Diagnosis of hormonerefractory prostate cancer Completed protocol ABBOTTM00211 or ABBOTTM00244 within the past 30 days Disease progression OR Active in trial when doubleblind treatment period ended PATIENT CHARACTERISTICS: Age 19 and over Performance status Karnofsky 60100% Life expectancy Not specified Hematopoietic WBC at least 3,000/mm3 Absolute neutrophil count greater than 1,000/mm3 Platelet count at least 100,000/mm3 Hemoglobin at least 9 g/dL Hepatic Bilirubin less than 1.5 mg/dL AST and ALT no greater than 1.5 times upper limit of normal Renal Creatinine clearance at least 40 mL/min Cardiovascular No New York Heart Association class IIIV heart disease Pulmonary No significant pulmonary disease requiring chronic or pulse steroid therapy within the past 3 months Other Fertile patients must use 2 effective methods of contraception (1 must be barrier contraception) during and for 8 weeks after study No reason that would preclude study No significant comorbid condition that would preclude study PRIOR CONCURRENT THERAPY: Biologic therapy Not specified Chemotherapy At least 4 weeks since other prior cytotoxic chemotherapy No other concurrent cytotoxic chemotherapy Endocrine therapy Not specified Radiotherapy At least 4 weeks since prior radionuclides No concurrent radionuclides Surgery Not specified Other At least 4 weeks since prior investigational agents No concurrent antiretroviral therapy for HIVpositive patients No concurrent participation in another investigational study</criteria>
	<gender>Male</gender>
	<minimum_age>19 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2003</verification_date>
	<keyword>adenocarcinoma of the prostate</keyword>
	<keyword>recurrent prostate cancer</keyword>
	<keyword>stage IIB prostate cancer</keyword>
	<keyword>stage IIA prostate cancer</keyword>
	<keyword>stage III prostate cancer</keyword>
	<keyword>stage IV prostate cancer</keyword>
</DOC>